Filing Flows › Health Care › Lantheus Holdings (LNTH)
Lantheus Holdings (LNTH) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Lantheus Holdings (LNTH) Q3 2026 earnings results →
Q3 2026 Revenue up 2% year over year to $390M · 6¢ of every $1 of revenue kept as net profit · operating margin 8.3%
Lantheus Holdings made $390M in Q3 2026 (+2% Y/Y): PYLARIFY $239M, Definity $85.7M, Neuraceq $45.6M. Operating margin 8.3%, net earnings $22.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $389.9M in Q3 2026, up 2% year over year and roughly flat from the previous quarter. PYLARIFY was the largest line at 61% of revenue. Neuraceq added $25.1M year over year (up 123%), 426% of the total change. PYLARIFY declined 1%.
Gross margin was 62.4%, up 4.5 points from Q3 2025. Operating profit was $32.2M, a 8.3% margin (down 3.1 points year over year). Operating profit fell $11.4M even though revenue rose $5.9M versus Q3 2025, so costs grew faster than sales. Operating expenses grew 18% against revenue growth of 2%. The fastest-growing cost line was Research & development (+93%). Net earnings were $22.4M, down 19% year over year. The effective tax rate was -2.7%.
Operating cash flow was $102.0M (down 3% year over year), 456% of net earnings. Non-cash charges added back $22.9M of depreciation and amortization and $21.9M of share-based compensation. Working capital and other items added $34.8M. After capital expenditures ($2.0M), free cash flow as the company reports it was $99.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $390M | +2% | 8.3% | $22.4M | $102M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $388M | +3% | 25.8% | $75.0M | $92.2M |
| Q1 2026 | 10-Q | May 7, 2026 | $377M | +1% | 21.6% | $118M | $125M |
| Q4 2025 | 10-K | Feb 26, 2026 | $407M | +4% | 19.0% | $54.1M | $90.2M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $384M | +1% | 11.4% | $27.8M | $105M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $378M | -4% | 23.3% | $78.8M | $87.1M |
| Q1 2025 | 10-Q | May 7, 2025 | $373M | +0.8% | 27.4% | $72.9M | $108M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Lantheus Holdings
We are the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. We classify our products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Our leading Radiopharmaceutical Oncology products help healthcare professionals (“HCPs”) Find, Fight and Follow cancer. Our leading Precision Diagnostic products assist HCPs to Find and Follow diseases, with a focus in cardiology. Our Strategic Partnerships include biomarkers and digital solutions in support of our partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of our assets geographically.
In its own words, from its 10-K, filed Feb 26, 2025.
Lantheus Holdings against its In Vitro & In Vivo Diagnostic Substances peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +2% against the peers' median +2%. Operating margin: 8.3% against the peers' median -1.2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| LNTH Lantheus Holdings | Q3 2026 | $390M | +2% | 8.3% |
| IDXX Idexx Laboratories | Q3 2026 | $1.2B | +10% | 33.1% |
| QDEL QuidelOrtho | Q3 2026 | $619M | -12% | -1.2% |
| NEOG Neogen | Q1 FY27 | $223M | +6% | -0.8% |
| MYGN Myriad Genetics | Q3 2026 | $203M | -2% | -19.7% |
| TKNO Alpha Teknova | Q3 2026 | $12.7M | +22% | -25.2% |
| ICCC Immucell | Q2 2026 | $7.2M | +12% | 26.9% |
| NTLA Intellia Therapeutics | Q3 2026 | $7.2M | -48% | n/m |
| AWHL Aspira Women's Health | Q2 2026 | $2.0M | -15% | -89.7% |
Source: Lantheus Holdings 10-Q on SEC EDGAR · CIK 1521036 · In Vitro & In Vivo Diagnostic Substances
Guidance and outlook
13F: who owns LNTH and who is buying
More on LNTH
- How Lantheus Holdings makes money: revenue by segment
- Lantheus Holdings next earnings date and what analysts expect
- Lantheus Holdings stock forecast, price target and fair value
- Who owns Lantheus Holdings stock: holders, funds and Congress trades
- Lantheus Holdings guidance and outlook
- Is Lantheus Holdings a takeover target? LBO and rumors
- Lantheus Holdings recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Lantheus Holdings gross margin by quarter
- Lantheus Holdings operating margin by quarter
- Lantheus Holdings net income by quarter
- Lantheus Holdings free cash flow by quarter
- Lantheus Holdings R&D spending by quarter
- Lantheus Holdings capital expenditures by quarter
- Lantheus Holdings PYLARIFY revenue by quarter
- Lantheus Holdings Definity revenue by quarter
- Lantheus Holdings Neuraceq revenue by quarter